|Author(s)/Faculty: Carmen A. Puliafito, MD, MBA; Diana V. Do, MD; Harry W. Flynn Jr., MD; K. Bailey Freund, MD; John E. Legarreta, MD; Quan Dong Nguyen, MD, MSc; Philip J. Rosenfeld, MD, PhD; SriniVas R. Sadda, MD; Stephen G. Schwartz, MD, MBA; Michael W. Stewart, MD|
During the past decade, retinal pharmacology has come into its own. Intravitreal use of corticosteroids, anti-vascular endothelial growth factor (anti-VEGF) agents, and novel biologics are now standard-of-care therapies for some of ophthalmology's most challenging disorders, including neovascular age-related macular degeneration (AMD), retinal vein occlusion, proliferative diabetic retinopathy, and diabetic macular edema (DME). Research into these and other agents continues, allowing for expanded indications and more efficacious delivery.
In this issue of INTRAVITREAL INTERVENTIONS, coverage of the recent American Academy of Ophthalmology annual meeting includes second-year data from the LUCAS trial investigating the treat-and-extend protocol for anti-VEGF therapy for patients with wet AMD. Year 2 results of the VIVID DME and VISTA DME aflibercept trials are also previewed. Subanalyses of the HARBOR trial of ranibizumab for wet AMD offer greater knowledge about both the medication and the natural history of the condition.